Insilico Medicine Completes First-in-Patient Dosing of ISM3412, the Novel MAT2A Inhibitor for the Treatment of Locally Advanced/Metastatic Solid Tumors (IMAGE)

InSilico Medicine

Insilico Medicine Completes First-in-Patient Dosing of ISM3412, the Novel MAT2A Inhibitor for the Treatment of Locally Advanced/Metastatic Solid Tumors

Caption

The Phase 1 study consists of two parts: dose escalation and dose selection optimization, where participants will receive ISM3412 orally once daily, not only to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics properties and preliminary anti-tumor efficacy of ISM3412, but also to determine the recommended dose in further studies.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.